BOLT News and Press, Bolt Biotherapeutics Inc. From 05/15/24

2024-05-15 10:19:00 ET More on Bolt Biotherapeutics Bolt Biotherapeutics draws downgrades after portfolio shakeup Seeking Alpha’s Quant Rating on Bolt Biotherapeutics Historical earnings data for Bolt Biotherapeutics Financial information for Bolt Biot...

A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...

2024-05-15 08:33:32 ET More on Bolt Biotherapeutics Seeking Alpha’s Quant Rating on Bolt Biotherapeutics Historical earnings data for Bolt Biotherapeutics Financial information for Bolt Biotherapeutics Read the full article on Seeking Alpha For...

2024-05-15 08:30:06 ET More on premarket losers & stocks. SunPower: Tariffs Will Help, But Still A Lot Of Work Needed Prior Massive Stock Repurchases Have Put Retailer Big Lots Into Serious Financial Trouble SunPower: Major Difficulties For An Unscalable Business...

Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2 Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approx...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-03-21 16:54:19 ET More on Bolt Biotherapeutics Seeking Alpha’s Quant Rating on Bolt Biotherapeutics Historical earnings data for Bolt Biotherapeutics Read the full article on Seeking Alpha For further details see: Bolt Biotherapeutics GAAP EPS...

–   BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones –   BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts –   Cash balanc...

REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44 th Annual He...

-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA,...